Histone H4R3 Dimethyl Symmetric (H4R3me2s) Polyclonal Antibody

Background
Histones are basic nuclear proteins that are responsible for the nucleosome structure of the chromosomal fiber in eukaryotes. This structure consists of approximately 146 bp of DNA wrapped around a nucleosome, an octamer composed of pairs of each of the four core histones (H2A, H2B, H3, and H4). The chromatin fiber is further compacted through the interaction of a linker histone, H1, with the DNA between the nucleosomes to form higher order chromatin structures. This gene is intronless and encodes a member of the histone H4 family. Transcripts from this gene lack polyA tails; instead, they contain a palindromic termination element. This gene is found in a histone cluster on chromosome 1. This gene is one of four histone genes in the cluster that are duplicated; this record represents the centromeric copy.

Description
Histone H4R3 Dimethyl Symmetric (H4R3me2s) Polyclonal Antibody. Unconjugated. Raised in: Rabbit.

Formulation
Buffer: PBS with 0.05% proclin300, 50% glycerol, pH7.3.

Specificity
Human, Mouse, Rat, Broad Range

Isotype
IgG

Uniprot ID
P62805

Purification
Affinity Purified

Immunogen
A synthetic peptide corresponding to a sequence within amino acids 1-100 of human Histone H4 (NP_003529.1).

Storage
Shipped at 4°C. Upon receipt, store at -20°C. Avoid repeated freeze.

Alternative Names
H4R3me2s, H4, H4/n, H4F2, H4FN, FO108, HIST2H4, H4 Arginine 3 me2s

Application
WB, IHC, IF/ICC, DB, ELISA; Recommended dilution: WB 1:500 – 1:2000, IHC 1:50 - 1:200, IF/ICC 1:50 - 1:200, DB 1:500 - 1:2000, ELISA - recommended starting concentration is 1 μg/mL. Please optimize the concentration based on your specific assay requirements.

1. Yang F et. al. (June 2025). PRMT5 Promotes Pancreatic Cancer Tumorigenesis via Positive PRMT5/C-Myc Feedback Loop. MedComm (2020). 6(6):e70150.
2. Nalla K et. al. (November 2024). Epigallocatechin-3-gallate inhibit the protein arginine methyltransferase 5 and enhancer of Zeste homolog 2 in breast cancer both in vitro and in vivo. Arch Biochem Biophys. 763:110223.
3. Brown EJ et. al. (January 2024). PRMT5 inhibition shows in vitro efficacy against H3K27M-altered diffuse midline glioma, but does not extend survival in vivo. Sci Rep. 14(1):328.
4. Liu L et. al. (April 2023). TRAF6 Promotes PRMT5 Activity in a Ubiquitination-Dependent Manner. Cancers (Basel). 15(9)
5. Yin S et. al. (March 2023). CDK5-PRMT1-WDR24 signaling cascade promotes mTORC1 signaling and tumor growth. Cell Rep. 42(4):112316.